;PMID: 8155716
;source_file_1792.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..49] = [t:0..49]
;1)sentence:[e:55..156] = [t:55..156]
;2)section:[e:160..199] = [t:160..199]
;3)section:[e:203..321] = [t:203..321]
;4)sentence:[e:325..494] = [t:325..494]
;5)sentence:[e:495..631] = [t:495..631]
;6)sentence:[e:632..891] = [t:632..891]
;7)sentence:[e:892..1084] = [t:892..1084]
;8)sentence:[e:1085..1239] = [t:1085..1239]
;9)sentence:[e:1240..1471] = [t:1240..1471]
;10)sentence:[e:1472..1614] = [t:1472..1614]
;11)sentence:[e:1615..1882] = [t:1615..1882]
;12)sentence:[e:1884..2082] = [t:1884..2082]
;13)section:[e:2086..2130] = [t:2086..2130]

;section 0 Span:0..49
;Biochim Biophys Acta. 1994 Apr 13;1205(2):325-35.
(SEC
  (FRAG (NNP:[0..7] Biochim) (NNP:[8..15] Biophys) (NNP:[16..20] Acta)
        (.:[20..21] .) (CD:[22..26] 1994) (NNP:[27..30] Apr)
        (CD:[31..38] 13;1205) (-LRB-:[38..39] -LRB-) (CD:[39..40] 2)
        (-RRB-:[40..41] -RRB-) (::[41..42] :) (CD:[42..44] 32)
        (CD:[44..48] 5-35) (.:[48..49] .)))

;sentence 1 Span:55..156
;Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s
;to  different flavonoids.
;[55..62]:substance:"Isozyme"
;[103..107]:substance:"cDNA"
;[118..130]:cyp450:"CYP1A P-450s"
;[145..155]:substance:"flavonoids"
(SENT
  (NP-HLN
    (NP
      (NP
        (ADJP (NN:[55..62] Isozyme) (HYPH:[62..63] -)
          (ADJP-1 (-NONE-:[63..63] *P*)))
        (NML-2 (-NONE-:[63..63] *P*)))
      (CC:[64..67] and)
      (NP
        (ADJP (NN:[68..75] species) (HYPH:[75..76] -)
          (ADJP-1 (JJ:[76..84] specific)))
        (NML-2 (NN:[85..99] susceptibility))))
    (PP (IN:[100..102] of)
      (NP
        (ADJP (NN:[103..107] cDNA) (HYPH:[107..108] -)
              (VBN:[108..117] expressed))
         (NN:[118..123] CYP1A) (NNS:[124..130] P-450s)))
    (PP (TO:[131..133] to)
      (NP (JJ:[135..144] different) (NNS:[145..155] flavonoids)))
    (.:[155..156] .)))

;section 2 Span:160..199
;Tsyrlov IB, Mikhailenko VM, Gelboin HV.
(SEC
  (FRAG (NNP:[160..167] Tsyrlov) (NNP:[168..170] IB) (,:[170..171] ,)
        (NNP:[172..183] Mikhailenko) (NNP:[184..186] VM) (,:[186..187] ,)
        (NNP:[188..195] Gelboin) (NNP:[196..198] HV) (.:[198..199] .)))

;section 3 Span:203..321
;Laboratory of Molecular Carcinogenesis, National Cancer Institute, National 
;Institutes of Health, Bethesda, MD 20892.
(SEC
  (FRAG (NN:[203..213] Laboratory) (IN:[214..216] of) (NNP:[217..226] Molecular)
        (NNP:[227..241] Carcinogenesis) (,:[241..242] ,)
        (NNP:[243..251] National) (NNP:[252..258] Cancer)
        (NNP:[259..268] Institute) (,:[268..269] ,) (NNP:[270..278] National)
        (NNPS:[280..290] Institutes) (IN:[291..293] of) (NNP:[294..300] Health)
        (,:[300..301] ,) (NNP:[302..310] Bethesda) (,:[310..311] ,)
        (NNP:[312..314] MD) (CD:[315..320] 20892) (.:[320..321] .)))

;sentence 4 Span:325..494
;The inhibitory and stimulatory effects of six flavonoids with distinct 
;hydroxylation patterns on the recombinant and hepatic mouse and human CYP1A 
;P-450s were studied.
;[371..381]:substance:"flavonoids"
;[467..480]:cyp450:"CYP1A  P-450s"
(SENT
  (S
    (NP-SBJ-4
      (NP (DT:[325..328] The)
        (NML
          (NML (JJ:[329..339] inhibitory)
            (NML-3 (-NONE-:[339..339] *P*)))
          (CC:[340..343] and)
          (NML (JJ:[344..355] stimulatory)
            (NML-3 (NNS:[356..363] effects)))))
      (PP (IN:[364..366] of)
        (NP
          (NP (CD:[367..370] six) (NNS:[371..381] flavonoids))
          (PP (IN:[382..386] with)
            (NP (JJ:[387..395] distinct) (NN:[397..410] hydroxylation)
                (NNS:[411..419] patterns)))))
      (PP (IN:[420..422] on)
        (NP (DT:[423..426] the)
          (NML
            (NML
              (ADJP-2 (JJ:[427..438] recombinant) (CC:[439..442] and)
                      (JJ:[443..450] hepatic))
              (NN:[451..456] mouse)
              (NML-1 (-NONE-:[456..456] *P*)))
            (CC:[457..460] and)
            (NML
              (ADJP-2 (-NONE-:[460..460] *P*))
              (JJ:[461..466] human)
              (NML-1 (NN:[467..472] CYP1A) (NNS:[474..480] P-450s)))))))
    (VP (VBD:[481..485] were)
      (VP (VBN:[486..493] studied)
        (NP-4 (-NONE-:[493..493] *))))
    (.:[493..494] .)))

;sentence 5 Span:495..631
;cDNA-expressed mouse CYP1A1 and CYP1A2 differed in their  sensitivity to both
;hydroxylated and nonhydroxylated flavonoids, respectively.
;[495..499]:substance:"cDNA"
;[516..522]:cyp450:"CYP1A1"
;[527..533]:cyp450:"CYP1A2"
;[606..616]:substance:"flavonoids"
(SENT
  (S
    (NP-SBJ
      (NP
        (ADJP-3 (NN:[495..499] cDNA) (HYPH:[499..500] -)
                (VBN:[500..509] expressed))
        (NML-2 (NN:[510..515] mouse))
        (NN:[516..522] CYP1A1))
      (CC:[523..526] and)
      (NP
        (ADJP-3 (-NONE-:[526..526] *P*))
        (NML-2 (-NONE-:[526..526] *P*))
        (NN:[527..533] CYP1A2)))
    (VP (VBD:[534..542] differed)
      (PP (IN:[543..545] in)
        (NP
          (NP (PRP$:[546..551] their) (NN:[553..564] sensitivity))
          (PP (TO:[565..567] to)
            (NP (CC:[568..572] both)
              (NP (VBN:[573..585] hydroxylated)
                (NML-1 (-NONE-:[585..585] *P*)))
              (CC:[586..589] and)
              (NP (JJ:[590..605] nonhydroxylated)
                (NML-1 (NNS:[606..616] flavonoids)))))))
      (,:[616..617] ,)
      (ADVP (RB:[618..630] respectively)))
    (.:[630..631] .)))

;sentence 6 Span:632..891
;A  comparison between the mouse and human CYP1A2 revealed that
;alpha-naphthoflavone  and flavone did not change the benzo[a]pyrene
;3-hydroxylation activity of human  CYP1A2 but inhibited its 7-ethoxyresorufin
;and 7-methoxyresorufin O-dealkylation  activities.
;[674..680]:cyp450:"CYP1A2"
;[695..715]:substance:"alpha-naphthoflavone"
;[721..728]:substance:"flavone"
;[748..762]:substance:"benzo[a]pyrene"
;[798..804]:cyp450:"CYP1A2"
;[823..840]:substance:"7-ethoxyresorufin"
;[845..863]:substance:"7-methoxyresorufin"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[632..633] A) (NN:[635..645] comparison))
      (PP (IN:[646..653] between)
        (NP (DT:[654..657] the)
          (NML
            (NML (NN:[658..663] mouse)
              (NML-3 (-NONE-:[663..663] *P*)))
            (CC:[664..667] and)
            (NML (JJ:[668..673] human)
              (NML-3 (NN:[674..680] CYP1A2)))))))
    (VP (VBD:[681..689] revealed)
      (SBAR (IN:[690..694] that)
        (S
          (NP-SBJ (NN:[695..715] alpha-naphthoflavone) (CC:[717..720] and)
                  (NN:[721..728] flavone))
          (VP
            (VP (VBD:[729..732] did) (RB:[733..736] not)
              (VP (VB:[737..743] change)
                (NP
                  (NP (DT:[744..747] the)
                    (NML (NN:[748..762] benzo-LSB-a-RSB-pyrene)
                         (NN:[763..778] 3-hydroxylation))
                    (NN:[779..787] activity))
                  (PP (IN:[788..790] of)
                    (NP (JJ:[791..796] human) (NN:[798..804] CYP1A2))))))
            (CC:[805..808] but)
            (VP (VBD:[809..818] inhibited)
              (NP (PRP$:[819..822] its)
                (NML
                  (NML
                    (NML (NN:[823..840] 7-ethoxyresorufin)
                      (NML-1 (-NONE-:[840..840] *P*)))
                    (NML-2 (-NONE-:[840..840] *P*)))
                  (CC:[841..844] and)
                  (NML
                    (NML (NN:[845..863] 7-methoxyresorufin)
                      (NML-1 (NN:[864..878] O-dealkylation)))
                    (NML-2 (NNS:[880..890] activities))))))))))
    (.:[890..891] .)))

;sentence 7 Span:892..1084
;In contrast, hydroxylated flavonoids increased the  7-methoxyresorufin
;O-demethylation and acetanilide 4-hydroxylation activities of  cDNA-expressed
;human CYP1A2 and in human liver microsomes.
;[918..928]:substance:"flavonoids"
;[944..962]:substance:"7-methoxyresorufin"
;[983..994]:substance:"acetanilide"
;[1026..1030]:substance:"cDNA"
;[1047..1053]:cyp450:"CYP1A2"
(SENT
  (S
    (PP (IN:[892..894] In)
      (NP (NN:[895..903] contrast)))
    (,:[903..904] ,)
    (NP-SBJ (VBN:[905..917] hydroxylated) (NNS:[918..928] flavonoids))
    (VP (VBD:[929..938] increased)
      (NP
        (NP (DT:[939..942] the)
          (NML
            (NML
              (NML (NN:[944..962] 7-methoxyresorufin)
                   (NN:[963..978] O-demethylation))
              (NML-1 (-NONE-:[978..978] *P*)))
            (CC:[979..982] and)
            (NML
              (NML (NN:[983..994] acetanilide) (NN:[995..1010] 4-hydroxylation))
              (NML-1 (NNS:[1011..1021] activities)))))
        (PP
          (PP (IN:[1022..1024] of)
            (NP
              (ADJP (NN:[1026..1030] cDNA) (HYPH:[1030..1031] -)
                    (VBN:[1031..1040] expressed))
              (JJ:[1041..1046] human) (NN:[1047..1053] CYP1A2)))
          (CC:[1054..1057] and)
          (PP-LOC (IN:[1058..1060] in)
            (NP (JJ:[1061..1066] human) (NN:[1067..1072] liver)
                (NNS:[1073..1083] microsomes))))))
    (.:[1083..1084] .)))

;sentence 8 Span:1085..1239
;These compounds  inhibited the benzo[a]pyrene 3-hydroxylase activity of
;cDNA-expressed CYP1A1 and  CYP1A2s as well as in mouse and human liver
;microsomes.
;[1091..1100]:substance:"compounds"
;[1116..1144]:cyp450:"benzo[a]pyrene 3-hydroxylase"
;[1157..1161]:substance:"cDNA"
;[1172..1178]:cyp450:"CYP1A1"
;[1184..1191]:cyp450:"CYP1A2s"
(SENT
  (S
    (NP-SBJ (DT:[1085..1090] These) (NNS:[1091..1100] compounds))
    (VP (VBD:[1102..1111] inhibited)
      (NP
        (NP (DT:[1112..1115] the)
          (NML (NN:[1116..1130] benzo-LSB-a-RSB-pyrene)
               (NN:[1131..1144] 3-hydroxylase))
          (NN:[1145..1153] activity))
        (PP
          (PP (IN:[1154..1156] of)
            (NP
              (NP
                (ADJP-2 (NN:[1157..1161] cDNA) (HYPH:[1161..1162] -)
                        (VBN:[1162..1171] expressed))
                (NN:[1172..1178] CYP1A1))
              (CC:[1179..1182] and)
              (NP
                (ADJP-2 (-NONE-:[1182..1182] *P*))
                (NNS:[1184..1191] CYP1A2s))))
          (CONJP (RB:[1192..1194] as) (RB:[1195..1199] well)
                 (IN:[1200..1202] as))
          (PP-LOC (IN:[1203..1205] in)
            (NP
              (NP (NN:[1206..1211] mouse)
                (NML-1 (-NONE-:[1211..1211] *P*)))
              (CC:[1212..1215] and)
              (NP (JJ:[1216..1221] human)
                (NML-1 (NN:[1222..1227] liver) (NNS:[1228..1238] microsomes))))))))
    (.:[1238..1239] .)))

;sentence 9 Span:1240..1471
;Hydroxylated flavonoids  did not inhibit NADPH-cytochrome P-450
;oxidoreductase activity but inhibited  NADPH-2,6-dichlorophenolindophenol
;oxidoreductase activity in liver microsomes  and in microsomes from
;recombinant Hep G2 cells.
;[1253..1263]:substance:"flavonoids"
;[1281..1318]:substance:"NADPH-cytochrome P-450 oxidoreductase"
;[1343..1392]:substance:"NADPH-2,6-dichlorophenolindophenol oxidoreductase"
(SENT
  (S
    (NP-SBJ (VBN:[1240..1252] Hydroxylated) (NNS:[1253..1263] flavonoids))
    (VP
      (VP (VBD:[1265..1268] did) (RB:[1269..1272] not)
        (VP (VB:[1273..1280] inhibit)
          (NP
            (NML
              (NML
                (NML (NN:[1281..1286] NADPH))
                (HYPH:[1286..1287] -)
                (NML (NN:[1287..1297] cytochrome) (NN:[1298..1303] P-450)))
              (NN:[1304..1318] oxidoreductase))
            (NN:[1319..1327] activity))))
      (CC:[1328..1331] but)
      (VP (VBD:[1332..1341] inhibited)
        (NP
          (NML (NN:[1343..1377] NADPH-2,6-dichlorophenolindophenol)
               (NN:[1378..1392] oxidoreductase))
          (NN:[1393..1401] activity))
        (PP-LOC
          (PP (IN:[1402..1404] in)
            (NP (NN:[1405..1410] liver) (NNS:[1411..1421] microsomes)))
          (CC:[1423..1426] and)
          (PP (IN:[1427..1429] in)
            (NP
              (NP (NNS:[1430..1440] microsomes))
              (PP (IN:[1441..1445] from)
                (NP (JJ:[1446..1457] recombinant) (NN:[1458..1461] Hep)
                    (NN:[1462..1464] G2) (NNS:[1465..1470] cells))))))))
    (.:[1470..1471] .)))

;sentence 10 Span:1472..1614
;Structure-activity  relationships indicated the importance of hydroxyl groups
;in the 5- and  7-positions on the A ring of the flavane nucleus.
;[1598..1605]:substance:"flavane"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1472..1481] Structure) (HYPH:[1481..1482] -)
          (NN:[1482..1490] activity))
      (NNS:[1492..1505] relationships))
    (VP (VBD:[1506..1515] indicated)
      (NP
        (NP (DT:[1516..1519] the) (NN:[1520..1530] importance))
        (PP (IN:[1531..1533] of)
          (NP (NN:[1534..1542] hydroxyl) (NNS:[1543..1549] groups))))
      (PP-LOC (IN:[1550..1552] in)
        (NP
          (NP (DT:[1553..1556] the)
            (NML
              (NML (CD:[1557..1558] 5) (HYPH:[1558..1559] -)
                (NML-1 (-NONE-:[1559..1559] *P*)))
              (CC:[1560..1563] and)
              (NML (CD:[1565..1566] 7) (HYPH:[1566..1567] -)
                (NML-1 (NNS:[1567..1576] positions)))))
          (PP-LOC (IN:[1577..1579] on)
            (NP
              (NP (DT:[1580..1583] the) (NN:[1584..1585] A)
                  (NN:[1586..1590] ring))
              (PP (IN:[1591..1593] of)
                (NP (DT:[1594..1597] the) (NN:[1598..1605] flavane)
                    (NN:[1606..1613] nucleus))))))))
    (.:[1613..1614] .)))

;sentence 11 Span:1615..1882
;These hydroxyl groups  accounted for the inhibitory potency of chrysin on
;each of the activities of the  expressed P-450s, while presence of a hydroxyl
;group at the 4'-position on the B  ring decreased the inhibitory potency of
;naringenin compared to that of chrysin.
;[1678..1685]:substance:"chrysin"
;[1730..1736]:cyp450:"P-450s"
;[1843..1853]:substance:"naringenin"
;[1874..1881]:substance:"chrysin"
(SENT
  (S
    (NP-SBJ (DT:[1615..1620] These) (NN:[1621..1629] hydroxyl)
            (NNS:[1630..1636] groups))
    (VP (VBD:[1638..1647] accounted)
      (PP-CLR (IN:[1648..1651] for)
        (NP
          (NP (DT:[1652..1655] the) (JJ:[1656..1666] inhibitory)
              (NN:[1667..1674] potency))
          (PP (IN:[1675..1677] of)
            (NP (NN:[1678..1685] chrysin)))
          (PP (IN:[1686..1688] on)
            (NP
              (NP (DT:[1689..1693] each))
              (PP (IN:[1694..1696] of)
                (NP
                  (NP (DT:[1697..1700] the) (NNS:[1701..1711] activities))
                  (PP (IN:[1712..1714] of)
                    (NP (DT:[1715..1718] the) (VBN:[1720..1729] expressed)
                        (NNS:[1730..1736] P-450s)))))))))
      (,:[1736..1737] ,)
      (SBAR-ADV (IN:[1738..1743] while)
        (S
          (NP-SBJ
            (NP (NN:[1744..1752] presence))
            (PP (IN:[1753..1755] of)
              (NP
                (NP (DT:[1756..1757] a) (NN:[1758..1766] hydroxyl)
                    (NN:[1767..1772] group))
                (PP-LOC (IN:[1773..1775] at)
                  (NP
                    (NP (DT:[1776..1779] the)
                      (NML (CD:[1780..1781] 4) (SYM:[1781..1782] '))
                      (HYPH:[1782..1783] -) (NN:[1783..1791] position))
                    (PP-LOC (IN:[1792..1794] on)
                      (NP (DT:[1795..1798] the) (NN:[1799..1800] B)
                          (NN:[1802..1806] ring))))))))
          (VP (VBD:[1807..1816] decreased)
            (NP
              (NP (DT:[1817..1820] the) (JJ:[1821..1831] inhibitory)
                  (NN:[1832..1839] potency))
              (PP (IN:[1840..1842] of)
                (NP (NN:[1843..1853] naringenin))))
            (S-ADV
              (NP-SBJ (-NONE-:[1853..1853] *))
              (VP (VBN:[1854..1862] compared)
                (NP (-NONE-:[1862..1862] *))
                (PP-CLR (TO:[1863..1865] to)
                  (NP
                    (NP (DT:[1866..1870] that))
                    (PP (IN:[1871..1873] of)
                      (NP (NN:[1874..1881] chrysin)))))))))))
    (.:[1881..1882] .)))

;sentence 12 Span:1884..2082
;The ortho-orientation of a hydroxyl group on the B ring was of importance, 
;inasmuch as quercetin was more potent than morin as an inhibitor of 
;cDNA-expressed and hepatic microsomal monooxygenases.
;[1972..1981]:substance:"quercetin"
;[2003..2008]:substance:"morin"
;[2015..2024]:substance:"inhibitor"
;[2029..2033]:substance:"cDNA"
;[2067..2081]:substance:"monooxygenases"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1884..1887] The) (AFX:[1888..1893] ortho) (HYPH:[1893..1894] -)
          (NN:[1894..1905] orientation))
      (PP (IN:[1906..1908] of)
        (NP
          (NP (DT:[1909..1910] a) (NN:[1911..1919] hydroxyl)
              (NN:[1920..1925] group))
          (PP-LOC (IN:[1926..1928] on)
            (NP (DT:[1929..1932] the) (NN:[1933..1934] B) (NN:[1935..1939] ring))))))
    (VP (VBD:[1940..1943] was)
      (PP-PRD (IN:[1944..1946] of)
        (NP (NN:[1947..1957] importance)))
      (,:[1957..1958] ,)
      (SBAR-ADV (RB:[1960..1968] inasmuch) (IN:[1969..1971] as)
        (S
          (NP-SBJ (NN:[1972..1981] quercetin))
          (VP (VBD:[1982..1985] was)
            (ADJP-PRD
              (ADJP (RBR:[1986..1990] more) (JJ:[1991..1997] potent))
              (PP (IN:[1998..2002] than)
                (NP (NN:[2003..2008] morin))))
            (PP (IN:[2009..2011] as)
              (NP
                (NP (DT:[2012..2014] an) (NN:[2015..2024] inhibitor))
                (PP (IN:[2025..2027] of)
                  (NP
                    (NP
                      (ADJP (NN:[2029..2033] cDNA) (HYPH:[2033..2034] -)
                            (VBN:[2034..2043] expressed))
                      (NML-1 (-NONE-:[2043..2043] *P*)))
                    (CC:[2044..2047] and)
                    (NP (JJ:[2048..2055] hepatic)
                      (NML-1 (JJ:[2056..2066] microsomal)
                             (NNS:[2067..2081] monooxygenases)))))))))))
    (.:[2081..2082] .)))

;section 13 Span:2086..2130
;PMID: 8155716 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2086..2090] PMID) (::[2090..2091] :) (CD:[2092..2099] 8155716)
        (NN:[2100..2101] -LSB-) (NNP:[2101..2107] PubMed) (::[2108..2109] -)
        (NN:[2110..2117] indexed) (IN:[2118..2121] for)
        (NNP:[2122..2130] MEDLINE-RSB-)))
